News : clinical trial

View:
 

Found press releases

 

FURTHER STUDIES MAY BE REQUIRED FOR MOB-015

2/9/2012 1:59 AM EST  -   MOBERG DERMA AB
Moberg Derma AB (OMX: MOB) has analysed data from approximately fifty per cent of the patients in the ongoing open phase II study for MOB-015. Based on the analysis, the company assesses that there is low probability that the final results from the study will be sufficient for out-licensing the project. Further studies will probably be required before continuing to phase III. The ongoing phase II study will be...

Positive results on “Clinical trial on beneficial effects of long term MenaQ7® (...

1/16/2012 1:45 AM EST  -   NattoPharma ASA
The data are presently evaluated but already it may be concluded that the results are positive and that the primary efficacy parameters are met.
In 2007 NattoPharma initiated a 3-year clinical intervention study on the effects of MenaQ7® on bone and cardiovascular health, respectively. Recruitment for the study started in early 2008 and the last measurements have been completed in the fall of 2011. The...

MOBERG DERMA HAS COMPLETED RECRUITMENT FOR MOB-015 PHASE II CLINICAL STUDY

9/12/2011 2:30 AM EST  -   MOBERG DERMA AB
Moberg Derma AB (OMX: MOB) has successfully completed the recruitment of 237 patients with nail fungus (onychomycosis) to participate in the ongoing MOB-015 phase II study. MOB-015 is the company’s second-generation topical treatment for nail fungus.
The purpose of the study, which includes 237 patients, is to confirm the validity of the MOB-015 product concept and to provide the basis for a phase III program...
HensonFuerst Attorneys
 

HensonFuerst Uncovers More on Questionable Cancer Treatment Trials at Medical Ce...

2/23/2011 12:56 PM EST  -   CJA
Cancer patients in Florida, Illinois, North Carolina, South Carolina, and Virginia are exposed to unnecessary medical risks after participating in flawed cancer treatments based on discredited research from Duke University Medical Center
RALEIGH, North Carolina—After launching an investigation into faulty cancer research sponsored by Duke University Medical Center, personal injury law firm HensonFuerst reveals...

MOBERG DERMA REPORTS POSITIVE CLINICAL RESULTS FOR EMTRIX

2/2/2011 4:45 AM EST  -   MOBERG DERMA AB
Moberg Derma AB today reports positive results from a clinical trial of Emtrix. The trial included 75 patients with nail fungus (onychomycosis) and the results showed that 92% of the patients improved after 8 weeks of treatment. Already after 2 weeks, 77% of the patients were improved.
The open clinical trial was conducted at two clinical centers in Sweden during the second half of 2010. The purpose was to...

MOBERG DERMA IS GRANTED PERMIT TO INITIATE PHASE II-TRIAL FOR MOB-015

11/17/2010 2:00 AM EST  -   MOBERG DERMA AB
The Swedish Medical Products Agency has granted Moberg Derma permit to initiate a clinical phase II trial for MOB-015. MOB-015 is Moberg Dermas next generation topical treatment for nail fungus, with fungicidal, keratolytic and emollient properties.
Nail fungus (onychomycosis) chiefly manifests itself in thickening and discoloration of the nails. The disease is common, affecting about 100 million patients in...

MOBERG DERMA REPORTS POSITIVE PHASE II RESULTS FOR K201 AGAINST ATOPIC ECZEMA

11/20/2009 8:05 AM EST  -   MOBERG DERMA AB
Moberg Derma AB reports today positive results from a phase II clinical study for K201 against atopic eczema. The study which included 30 patients with mild to moderate eczema showed that treatment with K201 resulted in statistically significant improvement of clinical skin condition, skin barrier and skin hydration. The study results also indicated that K201 can prevent growth of commonly occurring bacteria in...
Peter Wolpert, CEO Moberg Derma
 

MOBERG DERMA REPORTS POSITIVE PHASE III RESULTS FOR K101 AGAINST NAIL FUNGUS

11/20/2008 8:50 AM EST  -   MOBERG DERMA AB
Moberg Derma AB reports today positive results from a phase III clinical study for K101 against nail fungus (onychomycosis). In the study, almost 500 patients were treated during six months with K101 or a placebo. The results showed that significantly more patients receiving K101 were cured of their fungal infection (p=0.001). The patients' subjective evaluation of the treatment effect revealed distinct benefits...